Moody's Says Alkermes (ALKS) FORWARD-5 Data is Credit-Positive Development

October 21, 2016 2:31 PM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Moody's Investors Service commented that the positive clinical data of Alkermes' (Nasdaq: ALKS) experimental depression drug ALKS-5461 is credit positive. There is no effect on Alkermes' ratings including the Ba3 Corporate Family Rating, or the negative rating outlook.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Credit Ratings

Related Entities

Moody's Investors Service

Add Your Comment